Spots Global Cancer Trial Database for Trial Of Pembrolizumab And Nintedanib
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trial Of Pembrolizumab And Nintedanib
Official Title: Phase Ib Trial Of Pembrolizumab And Nintedanib
Study ID: NCT02856425
Conditions
Study Description
Brief Summary: Both anti-angiogenesis and anti PD1 immunotherapy have shown beneficial efficacy in solid tumors and in particular in NSCLC. Therefore it is of interest to investigate whether the combination of these two approaches is tolerable. Moreover, comprehensive pre-clinical and clinical rationale sustain the hypothesis that anti-VEGF could synergize with immunotherapy for the benefit of the patients.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Gustave Roussy, Villejuif, Val De Marne, France
Institut Bergonié, Bordeaux, , France
Centre Léon Bérard, Lyon, , France
Hôpital Bichat, Paris, , France
IUCT--O, Toulouse, , France
Contact Details
Name: Aurélien Marabelle, MD
Affiliation: Gustave Roussy, Cancer Campus, Grand Paris
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
